Laboratorios Farmaceuticos Rovi SA 41L
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €87.70
- Day Range
- €87.10–87.10
- 52-Week Range
- €35.64–91.30
- Bid/Ask
- €87.15 / €87.30
- Market Cap
- €4.45 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 33.52
- Price/Sales
- 5.96
- Dividend Yield (Trailing)
- 1.48%
- Dividend Yield (Forward)
- 1.26%
- Total Yield
- 4.08%
Company Profile
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,111
- Website
- https://www.rovi.es
Comparables
Valuation
|
Metric
|
41L
|
NAMS
|
RJF
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.52 | — | 1.46 |
Price/Book Value | 8.66 | 4.18 | 1.22 |
Price/Sales | 5.96 | 234.49 | 0.78 |
Price/Cash Flow | 34.28 | — | 8.21 |
Price/Earnings
41L
NAMS
RJF
Financial Strength
|
Metric
|
41L
|
NAMS
|
RJF
|
|---|---|---|---|
Quick Ratio | 0.76 | 8.13 | 0.86 |
Current Ratio | 2.54 | 8.17 | 1.59 |
Interest Coverage | 214.29 | — | 12.40 |
Quick Ratio
41L
NAMS
RJF
Profitability
|
Metric
|
41L
|
NAMS
|
RJF
|
|---|---|---|---|
Return on Assets (Normalized) | 16.50% | −39.62% | 3.22% |
Return on Equity (Normalized) | 25.68% | −46.06% | 5.34% |
Return on Invested Capital (Normalized) | 22.75% | −48.63% | 4.43% |
Return on Assets
41L
NAMS
RJF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Wzqqrmxv | Nljf | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dmwjydy | Vdspyk | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cnqgwkhs | Tszghn | $114.2 Bil | |||
| Moderna Inc
MRNA
| Dmhjmkq | Ztydn | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Pzlpdpxg | Bdfx | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Lgrmqyhlz | Rjtmg | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nwfrhgfgl | Rnhwwmg | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tmvntszhk | Nlctlyp | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Qqgtktcv | Mdbd | $12.8 Bil | |||
| Incyte Corp
INCY
| Xhbgjxpwl | Qxpws | $12.2 Bil |